127930-09-0

Basic information

• Product Name: SUCROSEOCTASULFATESODIUM
• Synonyms: SUCROSEOCTASULFATESODIUM
• CAS NO: 127930-09-0
• Molecular Formula: C₁₂H₁₄O₃₅S₈*8Na
• Molecular Weight: 0
• Mol File: 127930-09-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: SUCROSEOCTASULFATESODIUM(CAS DataBase Reference)
• NIST Chemistry Reference: SUCROSEOCTASULFATESODIUM(127930-09-0)
• EPA Substance Registry System: SUCROSEOCTASULFATESODIUM(127930-09-0)

Safety Data

• Hazardous Substances Data: 127930-09-0(Hazardous Substances Data)

Usage

General Description

SUCROSEOCTASULFATESODIUM is a chemical compound that is derived from sucrose, a type of sugar, that has been reacted with octasulfuric acid to form a sulfated derivative. SUCROSEOCTASULFATESODIUM is commonly used in the production of personal care products, such as shampoos and body washes, as a surfactant and foaming agent. It is known for its ability to help create a rich lather and effectively remove dirt and oil from the skin and hair. SUCROSEOCTASULFATESODIUM is considered to be a safe and effective ingredient in cosmetic formulations and is approved for use by regulatory agencies.

Upstream product

• 57-50-1 Sucrose 
• 74135-13-0 ammonium salt of sucrose octasulfate 
• 74135-09-4 barium salt of sucrose octasulfate 

Relevant articles and documents

Tissue distribution of [14C]sucrose octasulfate following oral administration to rats.

PURPOSE: Aluminum sucrose octasulfate (SOS) is used clinically to prevent ulcers. Under physiologic conditions, the sodium salt of this drug can be formed. Our objective was to determine whether sodium SOS was absorbed when administered orally. In addition to furthering our understanding of aluminum SOS, this study also aimed to clarify how other polyanionic drugs, such as heparin and low-molecular-weight heparins, are absorbed. METHODS: [14C]-labeled and cold sodium SOS (60 mg/kg) were given to rats by stomach tube. Radioactivity was counted in gut tissue, gut washes, and nongut tissue (i.e., lung, liver, kidney, spleen, endothelial, and plasma samples) at 3 min, 6 min, 15 min, 30 min, 60 min, 4 h, and 24 h, and in urine and feces accumulated over 4 h and 24 h. RESULTS: Peak radioactivity was found in the tissue and washes of the stomach, ileum, and colon at 6 min, 60 min, and 4 h, respectively, showing progression through the gut. Gut recovery accounted for 84% of the dose at 6 min but only 12% of the dose at 24 h, including counts from feces. Radioactivity was recovered from nongut tissue (averaging 8.6% of the dose) and accumulated urine (18% of the dose at 24 h). When total body distribution was considered, the recovery of radioactivity was greater for the endothelium than for plasma (peak percentage of the dose was 65% at 15 min, 20% at 3 min, 5% from 20 to 240 min for the vena cava, aortic endothelium, and plasma, respectively). CONCLUSIONS: Results indicate that sodium SOS is absorbed, agreeing with previous studies demonstrating the oral absorption of other sulfated polyanions. Endothelial concentrations must be considered when assessing the pharmacokinetics of these compounds. The measured plasma drug concentrations reflect the much greater amounts of drug residing with the endothelium.

Method for preparing high potency sucralfate

Sucralfate is prepared in good yields and in newly useful form first by reacting sucrose with chlorosulfonic acid in 2-picoline. The amonium salt is then formed and reacted with aluminum chlorohydrate in specific sequence and alcoholic solvent. The two distinct products have unexpected pharmaceutical and physical characteristics. The oral liquid suspensions also must be critically formulated.